Haw Par Past Earnings Performance
Past criteria checks 4/6
Haw Par's earnings have been declining at an average annual rate of -6.8%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 12.4% per year. Haw Par's return on equity is 4.2%, and it has net margins of 81.5%.
Key information
-6.8%
Earnings growth rate
-6.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -12.4% |
| Return on equity | 4.2% |
| Net Margin | 81.5% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Haw Par makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 182 | 148 | 55 | 0 |
| 30 Sep 22 | 176 | 141 | 57 | 0 |
| 30 Jun 22 | 171 | 134 | 58 | 0 |
| 31 Mar 22 | 156 | 122 | 54 | 0 |
| 31 Dec 21 | 141 | 110 | 49 | 0 |
| 30 Sep 21 | 119 | 96 | 41 | 0 |
| 30 Jun 21 | 96 | 82 | 34 | 0 |
| 31 Mar 21 | 104 | 101 | 34 | 0 |
| 31 Dec 20 | 111 | 120 | 35 | 0 |
| 30 Sep 20 | 140 | 118 | 40 | 0 |
| 30 Jun 20 | 181 | 161 | 49 | 0 |
| 31 Mar 20 | 211 | 206 | 52 | 0 |
| 31 Dec 19 | 244 | 182 | 61 | 0 |
| 30 Sep 19 | 253 | 190 | 63 | 0 |
| 30 Jun 19 | 257 | 190 | 64 | 0 |
| 31 Mar 19 | 251 | 182 | 66 | 0 |
| 31 Dec 18 | 238 | 179 | 62 | 0 |
| 30 Sep 18 | 233 | 173 | 63 | 0 |
| 30 Jun 18 | 226 | 156 | 64 | 0 |
| 31 Mar 18 | 222 | 125 | 66 | 0 |
| 31 Dec 17 | 223 | 122 | 68 | 0 |
| 30 Sep 17 | 222 | 128 | 63 | 0 |
| 30 Jun 17 | 218 | 130 | 58 | 0 |
| 31 Mar 17 | 210 | 128 | 56 | 0 |
| 31 Dec 16 | 202 | 125 | 53 | 0 |
| 30 Sep 16 | 189 | 124 | 55 | 0 |
| 30 Jun 16 | 187 | 116 | 56 | 0 |
Quality Earnings: HAWP.Y has high quality earnings.
Growing Profit Margin: HAWP.Y's current net profit margins (81.5%) are higher than last year (78%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HAWP.Y's earnings have declined by 6.8% per year over the past 5 years.
Accelerating Growth: HAWP.Y's earnings growth over the past year (34.7%) exceeds its 5-year average (-6.8% per year).
Earnings vs Industry: HAWP.Y earnings growth over the past year (34.7%) exceeded the Pharmaceuticals industry -17.3%.
Return on Equity
High ROE: HAWP.Y's Return on Equity (4.2%) is considered low.